Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3913 - RX-3117, an Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Advanced Urothelial Cancer

Date

10 Sep 2017

Session

Poster display session

Presenters

Manuel Maia

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

M.C. Maia1, S.K. Pal1, S.T. Tagawa2, V. Chung1, J. Picus3, S. Gupta4, J. Poore5, C. Peterson5, E. Benaim6

Author affiliations

  • 1 Department Of Medical Oncology & Experimental Therapeutics, City of Hope, 91010 - Duarte/US
  • 2 Genitourinary Oncology, Weill Cornell Medical College, 10065 - New York/US
  • 3 Internal Medicine, Washington University School of Mediciine, St. Louis/US
  • 4 Division Of Hematology, Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 5 Clinical Operations, Rexahn Pharmaceuticals, Inc, 20850 - Rockville/US
  • 6 Oncology, Rexahn Pharmaceuticals, 20850 - Rockville/US
More

Resources

Abstract 3913

Background

RX-3117 is an oral small-molecule hypomethylating agent, cyclopentyl pyrimidyl nucleoside that is activated by uridine cytidine kinase 2. RX-3117 shows efficacy in various xenograft models, including those of gemcitabine resistant bladder and colorectal cancers. Data from the stage 1 of a Phase 2a clinical study of RX-3117 as a single agent in subjects with advanced urothelial cancer are described below.

Methods

This Phase 2a study with a 2-stage design (NCT02030067) evaluates the efficacy of RX-3117 in eligible subjects (aged ≥ 18 years) with advanced urothelial cancer previously treated with an unlimited number of prior therapies. Primary objectives include safety and efficacy of the recommended Phase 2 dose (RP2D) and schedule identified in the Phase 1 portion of the study. Subjects received 700 mg of oral RX-3117 daily for 3 weeks with 1 week of rest in each 4-week cycle. The response criteria of complete response or partial response in 1 or more subjects or stable disease for 4 cycles in 2 or more subjects in Stage 1 in order to proceed to Stage 2.

Results

As of May 2017, 10 subjects with advanced urothelial cancer were treated with RX-3117 (4 females, 6 males). Of those 10 subjects, 70% received ≥ 3 prior therapies, had performance score of 0-1 and multiple disease sites (lung, liver, lymph nodes and pelvis). Two subjects met the protocol defined response criteria of stable disease for 4 cycles of RX-3117 treatment; one subject received treatment for 168 days and another subject continues receiving therapy (147 days at abstract submission). In addition, 1 subject showed tumor shrinkage as measured by RECIST (-15%); another subject still on treatment showed a 19% tumor reduction after 2 cycles of RX-3117. Related adverse events were G2 anemia, G1 anorexia, G1 epistaxis, G1 fatigue, G1 nausea, G1 diarrhea, G1/G2 vomiting, G2 mucositis, G3 leukopenia, G1/G3 neutropenia, and G3 thrombocytopenia. One subject had a treatment delay and dose reduction.

Conclusions

Single agent RX-3117 appears to be safe and well tolerated and shows evidence of preliminary tumor activity. The predefined efficacy criteria was met in Stage 1, and Stage 2 is ongoing. Results from Stage 1 of the phase 2a will be presented.

Clinical trial identification

NCT02030067

Legal entity responsible for the study

Rexahn Pharmaceuticals, Inc

Funding

Rexahn Pharmaceuticals, Inc

Disclosure

J. Poore, C. Peterson, E. Benaim: Employee of Rexahn Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.